There is ample evidence that arginine vasopressin (AVP) is a component of the neurohormonal response to congestive heart failure (CHF). Furthermore, AVP might play a role in the development, progression and worsening of CHF. Because of the need for further improvement in the treatment of CHF, randomized clinical trials were conducted to assess the efficacy and safety of non-peptide AVP receptor antagonists in patients with CHF. In pivotal trials of three non-peptide AVP receptor antagonists, these compounds improved the fluid status, osmotic balance and hemodynamics of patients with CHF. These studies support the approval of this class of agents for the symptomatic treatment of CHF, but long-term studies are required to demonstrate their role in the outcome and quality of life of these patients.

中文翻译：

---

血管加压素受体拮抗剂在心力衰竭中。

有足够的证据表明精氨酸加压素（AVP）是对充血性心力衰竭（CHF）的神经激素反应的组成部分。此外，AVP可能在CHF的发生，发展和恶化中起作用。由于需要进一步改善CHF的治疗，进行了随机临床试验以评估非肽AVP受体拮抗剂在CHF患者中的疗效和安全性。在三种非肽AVP受体拮抗剂的关键试验中，这些化合物改善了CHF患者的体液状态，渗透平衡和血液动力学。这些研究支持这类药物用于CHF的对症治疗，但需要长期研究证明其在这些患者的预后和生活质量中的作用。